William John Sempolinski Makes New Investment in GRAIL, Inc. $GRAL

William John Sempolinski purchased a new position in shares of GRAIL, Inc. (NASDAQ:GRAL) during the second quarter, Holdings Channel reports. The institutional investor purchased 7,150 shares of the company’s stock, valued at approximately $488,000.

Other institutional investors have also recently made changes to their positions in the company. Fifth Third Bancorp lifted its stake in GRAIL by 15,733.3% in the first quarter. Fifth Third Bancorp now owns 475 shares of the company’s stock worth $25,000 after acquiring an additional 472 shares during the period. Comerica Bank increased its position in GRAIL by 59.2% during the 3rd quarter. Comerica Bank now owns 465 shares of the company’s stock valued at $27,000 after purchasing an additional 173 shares during the period. Caitong International Asset Management Co. Ltd bought a new stake in shares of GRAIL in the 4th quarter valued at about $28,000. Geneos Wealth Management Inc. raised its holdings in shares of GRAIL by 160.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 585 shares of the company’s stock valued at $30,000 after purchasing an additional 360 shares in the last quarter. Finally, Elyxium Wealth LLC purchased a new stake in shares of GRAIL in the 4th quarter worth approximately $31,000.

GRAIL Stock Down 0.3%

GRAIL stock opened at $80.34 on Friday. The firm has a market cap of $3.59 billion, a price-to-earnings ratio of -8.24 and a beta of 3.25. GRAIL, Inc. has a 52 week low of $33.61 and a 52 week high of $118.84. The business’s 50-day moving average price is $72.54 and its 200 day moving average price is $62.97.

GRAIL (NASDAQ:GRAL) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($2.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.66) by $0.10. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%. The firm had revenue of $44.69 million for the quarter, compared to the consensus estimate of $42.39 million. Equities analysts expect that GRAIL, Inc. will post -10.41 EPS for the current year.

Insider Buying and Selling

In other news, CFO Aaron Freidin sold 7,900 shares of the company’s stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $85.01, for a total transaction of $671,579.00. Following the completion of the transaction, the chief financial officer directly owned 253,083 shares of the company’s stock, valued at $21,514,585.83. This represents a 3.03% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Joshua Ofman sold 5,000 shares of the stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $85.02, for a total value of $425,100.00. Following the transaction, the chief executive officer owned 397,271 shares in the company, valued at $33,775,980.42. This trade represents a 1.24% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.83% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research analysts have recently issued reports on GRAL shares. The Goldman Sachs Group initiated coverage on GRAIL in a report on Friday, June 5th. They issued a “neutral” rating and a $60.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a research note on Friday, July 17th. Mizuho raised their price objective on GRAIL from $58.00 to $65.00 and gave the company a “neutral” rating in a research report on Wednesday, July 15th. Wolfe Research began coverage on GRAIL in a research note on Tuesday, June 2nd. They issued a “peer perform” rating on the stock. Finally, Wall Street Zen downgraded shares of GRAIL from a “hold” rating to a “sell” rating in a report on Saturday. Four investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $67.78.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.